Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions? Patil T, Bunn PA. Clin Cancer Res 2022;28:2204-2205.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Patil T, Bunn PA. Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions? Clin Cancer Res 2022;28:2204-2205.
PMID: 35320359